Skip to Main Content

As a long-running battle over access to a pricey cystic fibrosis drug grinds on in the U.K., an advocacy group and several families have formed a buyer’s club in order to make a lower-cost version of a Vertex Pharmaceuticals (VRTX) treatment available to patients in the next few weeks.

The new buyer’s club is working with Gador, a drug maker based in Argentina, which will ship a generic version of the Orkambi medication to the U.K., where cystic fibrosis patients and their families can expect to pay roughly $25,000 a year, depending on how many people sign up. This would be 80 percent less than the approximately $132,000 that Vertex reportedly wants to charge the National Health Service in England.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED